Connect Biopharma (CNTB) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Connect Biopharma (CNTB) has outperformed Stablecoin Development (SDEV) over the past year, losing 80.6% versus a loss of 88.4%. Over five years, CNTB leads with a -86.9% price change compared with -100.0% for SDEV. Connect Biopharma is the larger company by market cap ($38.0 million vs $36.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | SDEV |
|---|---|---|
| Share price | $0.59 | $0.50 |
| Market cap | $38.05M | $36.90M |
| 1-day change | -6.08% | -10.30% |
| YTD return | -79.08% | -98.23% |
| 1-year return | -80.59% | -88.37% |
| 5-year return | -86.89% | -99.98% |
| P/E ratio (TTM) | — | 0.19 |
| EPS (TTM) | $-1.14 | $2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $64.00K | — |
| Revenue growth (YoY) | -99.75% | — |
| Net income (latest FY) | $-55.48M | $-630.78M |
| Operating margin | -90740.63% | — |
| Net margin | -86687.50% | — |
| 52-week high | $3.82 | $99.75 |
| 52-week low | $0.55 | $0.467 |
| Distance from 52-week high | -84.55% | -99.50% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +896.61% | — |
| Average volume | 3.98M | 16.98M |
| Shares outstanding | 64.49M | 73.80M |
| Employees | 64 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
CNTB vs SDEV FAQ
Which is bigger, Connect Biopharma or Stablecoin Development?
Connect Biopharma (CNTB) is larger, with a market capitalization of $38.05M compared with $36.90M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, CNTB or SDEV?
CNTB returned -80.59% over the past 12 months, compared with -88.37% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.